NASDAQ:CMRA Comera Life Sciences (CMRA) Stock Price, News & Analysis → Bigger Than NVIDIA? (From Behind the Markets) (Ad) Free CMRA Stock Alerts $0.02 0.00 (0.00%) (As of 10:06 AM ET) Add Compare Share Share Today's Range$0.03▼$0.0350-Day Range$0.02▼$0.0652-Week Range$0.02▼$0.74Volume610 shsAverage Volume19,360 shsMarket Capitalization$768,500.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends Get Comera Life Sciences alerts: Email Address Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> About Comera Life Sciences Stock (NASDAQ:CMRA)Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.Read More CMRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMRA Stock News HeadlinesMay 13, 2024 | msn.comCarisma Therapeutics to Join Citizens JMP Life Sciences ConferenceJanuary 31, 2024 | msn.comComera Life Sciences Announces Sweeping Workforce TerminationJune 18, 2024 | Behind the Markets (Ad)The Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.January 4, 2024 | finance.yahoo.comComera Life Sciences Announces Bridge Financing and Exercise of Take Private OptionJanuary 4, 2024 | finance.yahoo.comComera Life Sciences Announces Bridge Financing and Exercise of Take Private OptionDecember 6, 2023 | msn.comComera Life Sciences to explore strategic alternativesDecember 6, 2023 | finance.yahoo.comComera Life Sciences Announces Process Exploring Strategic AlternativesNovember 26, 2023 | benzinga.comComera Life Sciences Stock (NASDAQ:CMRA), Analyst Ratings, Price Targets, PredictionsJune 18, 2024 | Behind the Markets (Ad)The Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.November 14, 2023 | finance.yahoo.comComera Life Sciences Designates Dorothy Clarke to Board of DirectorsNovember 13, 2023 | finance.yahoo.comComera Life Sciences Appoints Dorothy Clarke to Board of DirectorsNovember 9, 2023 | msn.comComera Life Sciences GAAP EPS of -$0.10, revenue of $0.14MNovember 9, 2023 | finance.yahoo.comComera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business HighlightsOctober 18, 2023 | finance.yahoo.comComera Life Sciences Advancing Subcutaneous Monoclonal Antibody FormulationsOctober 16, 2023 | finance.yahoo.comComera Life Sciences Presents SQore™ Platform Technology Data at PODD: Partnerships in Drug Delivery ConferenceSeptember 13, 2023 | benzinga.comMassive Insider Trade At Comera Life SciencesSeptember 12, 2023 | benzinga.com10% Owner At This Health Care Company Buys $1.05M of StockSeptember 12, 2023 | finance.yahoo.comComera Life Sciences Announces the Completion of $4.1 Million Private PlacementAugust 16, 2023 | finance.yahoo.comComera Study Shows Caffeine’s Ability to Reduce Viscosity in AntibodiesAugust 16, 2023 | finance.yahoo.comComera Life Sciences Announces Publication of Study Reinforcing Caffeine’s Viscosity Reducing CapabilitiesAugust 10, 2023 | finance.yahoo.comComera Life Sciences Reports Financial Results for Second Quarter 2023 and Recent Business HighlightsAugust 8, 2023 | finance.yahoo.comComera Life Sciences Boosts SQore Platform PatentsAugust 8, 2023 | finance.yahoo.comComera Life Sciences Significantly Expands Intellectual Property Portfolio Strengthening the Proprietary SQore™ PlatformAugust 2, 2023 | finance.yahoo.comComera Life Sciences Announces $4.1 Million Private PlacementAugust 1, 2023 | finance.yahoo.comComera Life Sciences Announces $4.1 Million Private PlacementJuly 24, 2023 | finance.yahoo.comComera Partners with Quality Chemical Laboratories to Strengthen Supply ChainJuly 15, 2023 | seekingalpha.comCMRA Comera Life Sciences Holdings, Inc.See More Headlines Receive CMRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Comera Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CMRA CUSIPN/A CIK1907685 Webcomeralifesciences.com Phone617-871-2101FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,000,000.00 Net Margins-904.00% Pretax Margin-901.00% Return on EquityN/A Return on Assets-297.91% Debt Debt-to-Equity RatioN/A Current Ratio0.90 Quick Ratio0.90 Sales & Book Value Annual Sales$630,000.00 Price / Sales1.22 Cash FlowN/A Price / Cash FlowN/A Book Value($0.37) per share Price / Book-0.07Miscellaneous Outstanding Shares30,740,000Free Float28,002,000Market Cap$768,500.00 OptionableNot Optionable Beta0.08 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Michael G. Campbell CPA (Age 55)CEO, CFO & Principal Accounting Officer Comp: $269.11kDr. David Soane Ph.D.Co-Founder & Member of Scientific Advisory BoardMs. Janice Marie McCourt B.S. (Age 62)CLP, M.B.A., R.Ph., Chief Business Officer Key CompetitorsNovaBay PharmaceuticalsNYSE:NBYExicureNASDAQ:XCURAraviveNASDAQ:ARAVQuoin PharmaceuticalsNASDAQ:QNRXBiophytisNASDAQ:BPTSYView All CompetitorsInsidersCharles CheringtonBought 2,053,789 shares on 9/11/2023Total: $1.05 M ($0.51/share)Robert Patrick MahoneyBought 20,000 shares on 8/14/2023Total: $12,600.00 ($0.63/share)David SoaneBought 273,838 shares on 7/31/2023Total: $139,657.38 ($0.51/share)View All Insider Transactions CMRA Stock Analysis - Frequently Asked Questions How have CMRA shares performed in 2024? Comera Life Sciences' stock was trading at $0.0550 on January 1st, 2024. Since then, CMRA shares have decreased by 54.5% and is now trading at $0.0250. View the best growth stocks for 2024 here. How do I buy shares of Comera Life Sciences? Shares of CMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CMRA) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Comera Life Sciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Comera Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
